Plain-English translation of NCT03215719 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating HPV-positive oropharyngeal cancer (a type of throat cancer). Instead of giving all patients the same radiation dose, researchers want to see if they can reduce the radiation dose for patients whose tumors shrink quickly during treatment. The goal is to keep cancer control just as good while reducing long-term side effects like trouble swallowing or dry mouth.
Standard radiation therapy for throat cancer can cause lasting problems with swallowing, eating, and saliva production. Since HPV-positive throat cancers tend to respond very well to treatment, doctors believe some patients might need less radiation. This trial is designed to find out if we can personalize treatment based on how quickly a patient's cancer responds.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy (cisplatin) once a week for either 5, 6, or 7 weeks paired with daily radiation therapy. Your specific radiation dose and treatment length will depend on how well your tumor shrinks in the first few weeks—doctors will check this with a CT scan at week 4. You will also have blood tests to check for HPV DNA levels. Throughout and after treatment, you will complete quality-of-life questionnaires and return for follow-up visits to check for cancer recurrence and any side effects for at least 2 years.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States